中投顾问

24小时免费服务热线400-008-1522

Investment and Forecast Report on China Chemical Medicine Industry, 2024-2028

首次出版:最新修订:August 2012交付方式:特快专递(2-3天送达)

报告属性:共0页下载目录 版权声明

定购电话:0755-82571522、82571566、400-008-1522

24小时服务热线:138 0270 8576 定制报告

版本 在线版 电子版印刷版 电子版+印刷版
优惠价 RMB 6800 RMB 7600 RMB 7800
原价 RMB 9600 RMB 9600 RMB 9800

立即订购 加入购物车 QQ咨询 在线客服

优惠权益

订购报告,即可获得以下权益:

权益一:加1送1 ——加1000元、送1份在线版研究报告,多加多送,数量不限;了解在线版报告详细清单,请点击咨询 >

权益二:加1送2——加1000元,送2个独家数据库,即上市公司投资项目库和企业拿地投资数据库; 了解中投大数据 >

权益三:加1送200——加1000元,送超过200条在线版产业链图谱,使用期限为1年; 查看产业链图谱清单 >

中投顾问重磅推出产业研究大脑,是"产业研究的数字化高效工具",欢迎试用体验!

产品名称 目标用户 核心功能定位 产品介绍 试用申请
产业研究大脑 政府、企业内关注产业发展的领导及工作人员 产业研究工作的一站式解决方案 详情 > 申请 >
X

申请试用

请完善以下信息,我们顾问会在一个工作日内与您联系

*姓名

*手机号

*政府/园区/机构/企业名称

您的职务

您的邮箱

备注

立即申请

X

您的需求已经提交!

如果您希望尽早试用体验,也可以直接联系我们。

联系电话:   400 008 0586;   0755-82571568

微信扫码:   扫码咨询

报告目录内容概述 定制报告

ChapterⅠPharmaceutical industry
  1.1 Overview of international pharmaceutical industry
    1.1.1 Overview of the development of the global pharmaceutical industry
    1.1.2 Large-scale mergers and acquisitions in the global pharmaceutical industry have started
    1.1.3 Analysis of the global pharmaceutical industry in 2010
    1.1.4 Analysis of the global pharmaceutical market ’ development in 2011
    1.1.5 Forecast of development of the global pharmaceutical market
  1.2 Overview of the domestic pharmaceutical industry in general
    1.2.1 The development course of China's pharmaceutical industry in the past three decades since the reform and opening up
    1.2.2 Chinese pharmaceutical industry is in the critical period of adjustment and upgrade
    1.2.3 Multinational pharmaceutical companies in China's pharmaceutical market
    1.2.4 The main trend of mergers and acquisitions of the domestic pharmaceutical market
  1.3 Data analysis of the pharmaceutical industry in 2008-2012
    1.3.1 Analysis of operation data of the pharmaceutical industry in 2008
    1.3.2 The development of Chinese pharmaceutical industry in 2009
    1.3.3 The operations of China's pharmaceutical industry in 2010
    1.3.4 Operation analysis of China's pharmaceutical industry in 2011
    1.3.5 The operations of China's pharmaceutical industry in 2012
  1.4 Analysis of the rural medical market
    1.4.1 Basic rural medical market
    1.4.2 The situation of township and rural medical market
    1.4.3 Characteristics of rural medical market
    1.4.4 Channel problems hinder the development of the rural medical market
  1.5 Analysis of the mode of mergers and acquisitions in pharmaceutical market
    1.5.1 The difference between domestic and international M & A activities
    1.5.2 Risk of M & A
    1.5.3 Mode of M & A
  1.6 Problems in the pharmaceutical industry and its countermeasures
    1.6.1 Problems in Chinese pharmaceutical industry
    1.6.2 Government should strengthen policy guidance
    1.6.3 The increasing concentration of the pharmaceutical industry
    1.6.4 Chinese pharmaceutical industry is exploring the international road
ChapterⅡ Chemical medicine industry
  2.1 Development of China’s chemical pharmaceutical industry in 2008-2010
    2.1.1 Development of China’s chemical pharmaceutical industry in 2008
    2.1.2 Development of China’s chemical pharmaceutical industry in 2009
    2.1.3 Development of China’s chemical pharmaceutical industry in 2010
  2.2 The development of China’s chemical pharmaceutical industry in 2011
    2.2.1 The share of GDP The industrial output value of chemical medicine change
    2.2.2 The proportions of chemical medicine sector investment to total investment
    2.2.3 Supply analysis of China’s chemical pharmaceutical industry
    2.2.4 Demand analysis of China’s chemical pharmaceutical industry
  2.3 Analysis of domestic chemical and pharmaceutical companies
    2.3.1 Analysis of the competitive environment for the pharmaceutical companies
    2.3.2 Characteristics of domestic chemical and pharmaceutical companies
    2.3.3 Impact of inward international business on China’s chemical pharmaceutical enterprises
    2.3.4 Resources integration drive the development of pharmaceutical companies in the post-GMP era
    2.3.5 Profit model for China’s chemical pharmaceutical companies
Chapter Ⅲ Financial analysis of China’s pharmaceutical preparations manufacturing industry
  3.1 Economic scale of China’s chemical preparations manufacturing industry
    3.1.1 Sales scale of China’s chemical preparations manufacturing industry during 2008-Jun 2012
    3.1.2 Profit scale of China’s chemical preparations manufacturing industry during  2008-Jun 2012
    3.1.3 Asset scale of China’s chemical preparations manufacturing industry during  2008-Jun 2012
  3.2 Profitability analysis of China’s pharmaceutical preparations manufacturing industry
    3.2.1 Loss-generating enterprises preparations of chemical preparations manufacturing industry during  2008-Jun 2012
    3.2.2 Gross margin of chemical preparations manufacturing industry during  2008-Jun 2012
    3.2.3 Cost and expense ratios of chemical preparations manufacturing industry during  2008-Jun 2012
    3.2.4 Rate of return on sale of chemical preparations manufacturing industry during  2008-Jun 2012
  3.3 Analysis of enterprises' operating capacity for China’s chemical preparations manufacturing industry
    3.3.1 Accounts receivable turnover of China’s chemical preparations manufacturing industry during  2008-Jun 2012
    3.3.2 Current assets turnover of China’s chemical preparations manufacturing industry during  2008-Jun 2012
    3.3.3 Total assets turnover of China’s chemical preparations manufacturing industry during  2008-Jun 2012
  3.4 Debt-paying ability analysis of China’s chemical preparations manufacturing industry
    3.4.1 Asset-liability ratio of China’s chemical preparations manufacturing industry during  2008-Jun 2012
    3.4.2 Interest cover ratio of China’s chemical preparations manufacturing industry during  2008-Jun 2012
  3.5 Comprehensive evaluation of financial situation of Chinese chemical preparations manufacturing
    3.5.1 Comprehensive evaluation of financial situation of chemical preparations manufacturing
    3.5.2 Economic factors which impact the financial condition of chemical preparations manufacturing
Chapter Ⅳ Financial analysis of China’s chemical raw medicine manufacturing industry
  4.1 Economic scale of China’s chemical raw medicine manufacturing industry
    4.1.1 Sales scale of China’s chemical raw medicine manufacturing industry during 2008-Jun 2012
    4.1.2 Profit scale of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.1.3 Asset scale of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
  4.2 Profitability analysis of China’s chemical raw medicine manufacturing industry
    4.2.1 Loss-generating enterprises preparations of chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.2.2 Gross margin of chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.2.3 Cost and expense ratios of chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.2.4 Rate of return on sale of chemical raw medicine manufacturing industry during  2008-Jun 2012
  4.3 Analysis of enterprises' operating capacity for China’s chemical raw medicine manufacturing industry
    4.3.1 Accounts receivable turnover of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.3.2 Current assets turnover of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.3.3 Total assets turnover of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
  4.4 Debt-paying ability analysis of China’s chemical raw medicine manufacturing industry
    4.4.1 Asset-liability ratio of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.4.2 Interest cover ratio of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
  4.5 Comprehensive evaluation of financial situation of Chinese chemical raw medicine manufacturing
    4.5.1 Comprehensive evaluation of financial situation of chemical raw medicine manufacturing
    4.5.2 Economic factors which impact the financial condition of chemical raw medicine manufacturing industry
Chapter V Analysis of the domestic chemical raw materials industry
  5.1 Status of chemical raw materials industry
    5.1.1 Low-priced exports of chemical raw materials lead to trade disputes
    5.1.2 Raw materials export is very hard for China
    5.1.3 Chemical raw materials industry mingled hope and fear
    5.1.4 Worries about China's chemical raw materials
  5.2 Chemical raw materials production in the major provinces of China during 2010- Jul 2012
    5.2.1 Chemical raw materials production in the major provinces of China in 2010
    5.2.2 Chemical raw materials production in the major provinces of China in 2011
    5.2.3 Chemical raw materials production in the major provinces of China during January to July 2012
  5.3 Import and export of chemical raw materials
    5.3.1China’s import and export of chemical raw materials in 2008
    5.3.2 Analysis of the exports of chemical raw materials in 2009
    5.3.3 Imports and exports of chemical raw materials in China in 2010
    5.3.4 Analysis of imports and exports of chemical raw materials in 2011
    5.3.5 Imports and exports of chemical raw materials in 2012
Chapter VI Analysis of antibiotics
  6.1 Overview of antibiotic-associated
    6.1.1 Definition and Classification
    6.1.2 Principles of antibiotics
    6.1.3 Use of antibiotics
  6.2 Antibiotics market analysis
    6.2.1 Development of the main varieties of domestic antibiotic
    6.2.2 Overview of U.S. antibiotics global trade situation
    6.2.3 Analysis of China’s antibiotics export
    6.2.4 Antibiotics is the largest amount of China's hospital clinical use
    6.2.5 Antibiotics Industrial Technology Innovation Alliance has set up
    6.2.6 China is facing a new business environment for development of antibiotics
  6.3 Analysis of cephalosporin antibiotics
    6.3.1 Definition and classification
    6.3.2 Import and export of cephalosporins
    6.3.3 Cephalosporin market rebound After the Chinese New Year of 2011
    6.3.4 Worries about China’s cephalosporins indusry in the rapid development
    6.3.5 Cephalosporin antibiotics have a stable market
    6.3.6 Cefprozil has much brighter future
  6.4 Tetracyclines antibiotics
    6.4.1 Overview of tetracyclic antibiotics
    6.4.2 Overview of world market tetracycline
    6.4.3 Analysis of China’s exports of tetracycline
    6.4.4 Prospect of China tetracycline
  6.5 Macrolides
    6.5.1 Overview of macrolide antibiotic-associated
    6.5.2 Progress in research and development of macrolide antibiotics
    6.5.3 Analysis of macrolide export
    6.5.4 Macrolide antibiotics had stong momentum
    6.5.5 Analysis of the second-generation macrolide antibiotics
  6.6 Quinolones
    6.6.1 The development of quinolones
    6.6.2 Pharmacology and medicinal
    6.6.3 China developed gatifloxacin class of drugs of China own proprietary first time
Chapter VII The vitamins API
  7.1 Overview of the international market
    7.1.1 Opportunities and challenges coexist in world vitamin industry
    7.1.2 The composition of the international vitamin market
    7.1.3 A new pattern of competition of global vitamin industry
    7.1.4 International vitamin market trends
  7.2 Overview of domestic vitamin market
    7.2.1 Overview of Chinese vitamin industry
    7.2.2 The domestic vitamin market in 2009
    7.2.3 Analysis of China's exports of vitamins in 2010
    7.2.4 Overview of China vitamin market in 2011
    7.2.5 The future development potential of vitamin industry
  7.3 Analysis of fat-soluble vitamins
    7.3.1 Introduction of fat-soluble vitamins
    7.3.2 Market analysis of vitamin AD
    7.3.3 Vitamin D2 has a bright market future
    7.3.4 Vitamin D production exceeded multinational monopoly
  7.4 Analysis of water-soluble vitamins
    7.4.1 Introduction of water-soluble vitamins
    7.4.2 Analysis of China's exports of vitamin C in 2011
    7.4.3 Market situation of vitamin B2 in domestic market
    7.4.4 Vitamin B12 and its derivatives have broad market prospects
    7.4.5 China has achieved self-sufficiency in the production of Vitamin H
Chapter VIII Analysis on the drugs of major category
  8.1 Diabetes drugs
    8.1.1 Development of the global diabetes drug market
    8.1.2 New technologies will break the pattern of the global diabetes drug market
    8.1.3 Domestic and foreign pharmaceutical companies compete for the Chinese diabetes drug market
    8.1.4 Sale pattern of diabetes drug market
    8.1.5 Forecast of China diabetes drug market 2012
  8.2 Cardiovascular drugs
    8.2.1 Summary of U.S. cardiovascular drugs market development
    8.2.2 Summary of cardiovascular drugs market in China
    8.2.3 Competition pattern of China cardiovascular drug market
    8.2.4 China antihypertensive drugs market grow fast
    8.2.5 Foreign brands dominated the domestic market of antihypertensive drugs
  8.3 Cold medicine
    8.3.1 Consumer behavior analysis on Chinese cold medicine market
    8.3.2 Chinese cold medicine retail market structure analysis
    8.3.3 Impact of "restricted order" on the domestic cold drug market
    8.3.4 Cold medicine marketing strategies
    8.3.5 Cold medicine suffered a crisis of confidence and measures in 2011
  8.4 Other drugs
    8.4.1 Market structure of China non-steroidal anti-inflammatory drugs
    8.4.2 Non-steroidal anti-inflammatory drug market grow rapidly
    8.4.3 Overview of antiviral drug market
    8.4.4 Bright prospect of anti-allergic rhinitis drug market
Chapter IX Analysis of listed companies
  9.1 Harbin Pharmaceutical Group Co., Ltd.(HPGC)
    9.1.1 Introduction
    9.1.2 Operating analysis of HPGC in 2010
    9.1.3 Operating analysis of HPGC in 2011
    9.1.4 Operating analysis of HPGC in the first half of 2012
    9.1.5 HPGC actively widen the innovative platform
  9.2 North China Pharmaceutical Co., Ltd.(NCPC)
    9.2.1 Introduction
    9.2.2 Operating analysis of NCPC in 2010
    9.2.3 Operating analysis of NCPC in 2011
    9.2.4 Operating analysis of NCPC in the first half of 2012
    9.2.5 NCPC carry out the strategic transformation to promote preparation export
  9.3 Shandong Lukang Pharmaceutical Co.,Ltd. (LKPC)
    9.3.1 Introduction
    9.3.2 Operating analysis of LKPC in 2010
    9.3.3 Operating analysis of LKPC in 2011
    9.3.4 Operating analysis of LKPC in the first half of 2012
    9.3.5 Science and technology lead the new development of LKPC
  9.4 Guangzhou Baiyunshan Pharmaceutical Co.,Ltd..(BYS)
    9.4.1 Introduction
    9.4.2 Operating analysis of BYS in 2010
    9.4.3 Operating analysis of BYS in 2011
    9.4.4 Operating analysis of BYS in the first half of 2012
    9.4.5 BYS returns the professional management
  9.5 Zhejiang Hisun Pharmaceutical Co.,Ltd..(HISUN)
    9.5.1 Introduction
    9.5.2 Operating analysis of HISUN in 2010
    9.5.3 Operating analysis of HISUN in 2011
    9.5.4 Operating analysis of HISUN in the first half of 2012
    9.5.5 HISUN promote development by innovation
  9.6 Shandong Xinhua Pharmaceutical Company Limited(XHZY)
    9.6.1 Introduction
    9.6.2 Operating analysis of XHZY in 2010
    9.6.3 Operating analysis of XHZY in 2011
    9.6.4 Operating analysis of XHZY in the first half of 2012
    9.6.5 XHZY regard the Scientific and technological innovation as the core competitiveness
  9.7 Comparative Analysis of Listed Companies
    9.7.1 Profitability analysis
    9.7.2 Growth capacity
    9.7.3 Operating capacity
    9.7.4 Solvency capacity
Chapter X Medical logistics
  10.1 Development of China medical logistics industry
    10.1.1 Current situation of China medicine circulation
    10.1.2 Medical logistics industry is in the period of fully integration
    10.1.3 Characteristics of domestic and foreign medical logistics market
    10.1.4 Analysis on China medical logistics market
    10.1.5 China medical logistics market enters the distributor era
  10.2 Problems analysis on medical logistics
    10.2.1 Problems in China medical logistics
    10.2.2 Duplication of similarprojects and disorderly competition in China medical logistics industry
    10.2.3 Lack of talent in medical logistics
    10.2.4 Serious problem of distribution system in China medical logistics industry
  10.3 Development strategy of medical logistics
    10.3.1 Problems that should be paid attention to in medical logistics industry development
    10.3.2 Supply chain management is the key to develop modern medical logistics
    10.3.3 Domestic medical logistics industry should learn from foreign models
    10.3.4 Competitive strategy that China medical logistics companies compete with foreigners
    10.3.5 China should implement an active medical logistics development policy
  10.4 Case study
    10.4.1 Hong Kong Zuellig Group
    10.4.2 Shenzhen Accord Pharmaceutical Co., Ltd.
    10.4.3 Information creates "Jinxiang Pharmacy " Medical Logistics
  10.5 Prospects of medical logistics industry
    10.5.1 Development prospects of China medical logistics industry
    10.5.2 China medical logistics market trends
    10.5.3 Refrigerated logistics will become the key development area in medical logistics industry
    10.5.4 SWOT analysis on medical logistics development model
Chapter XI Pharmaceutical Marketing
  11.1 Status of pharmaceutical marketing
    11.1.1 Dilemma of China pharmaceutical marketing
    11.1.2 Marketing pattern in GMP post-certification era
    11.1.3 Strange situations in pharmaceutical marketing
  11.2 Analysis of pharmaceutical marketing model
    11.2.1 Total-propaganda marketing model
    11.2.2 Clinic-marketing model
    11.2.3 Conference marketing model
    11.2.4 Advertising hype plus terminal marketing model
    11.2.5 Marketing model innovation about pharmaceutical product
    11.2.6 "SICHUAN SHUZHONG MEDICINE GROUP mode" revitalize generic drugs marketing of the rural market
  11.3 Analysis of pharmaceutical marketing problems
    11.3.1 Two drawbacks of pharmaceutical marketing
    11.3.2 Three mistakes in making pharmaceutical marketing strategy
    11.3.3 Five difficulties on developing rural medical market
    11.3.4 Five marketing difficulties that pharmaceutical companies need to solve
  11.4 Measures of pharmaceutical marketing development
    11.4.1 Marketing strategies after the pharmaceutical reform
    11.4.2 In-depth planning is the direction of pharmaceutical marketing
    11.4.3 Analysis on rural marketing ideas
    11.4.4 Marketing systematic is help with developing the rural market
  11.5 Typical case study
    11.5.1 "white and black" was born to be alive by channel
    11.5.2 Johnson Tylenol find the right way and win opportunities
    11.5.3 The Successful Road of JIANGZHONG Jianweixiaoshi tablets
  11.6 Pharmaceutical marketing trends
    11.6.1 Ten new trends in pharmaceutical marketing
    11.6.2 Ten directions of pharmaceutical distributors development
    11.6.3 Future prospects of pharmaceutical marketing
    11.6.4 Marketing channels of pharmaceutical OTC market in future
Chapter XII Outlook on chemical medicine industry
  12.1 Outlook on China pharmaceutical industry
    12.1.1 Development prospects of pharmaceutical industry
    12.1.2 China pharmaceutical retail market has large space for growth
    12.1.3 Pharmaceutical market development trends
  12.2 Outlook on China chemical medicine industry
    12.2.1 Prospects of China API industry
    12.2.2 Fluorine chemistry will become the basis for new API drug
    12.2.3 Prospects of chemical preparation industry development
    12.2.4 Forecast analysis of China chemical pharmaceutical industry 2012-2016
Chapter XIII Policies and regulations
  13.1 Policy analysis
    13.1.1 The pharmaceutical industry entered into serious policy period through strictly controling drug prices
    13.1.2 Pharmaceutical companies faced two policy challenges
    13.1.3 Strong regulation of false drug advertising
    13.1.4 creating new drugs may obtain fast approval
  13.2 Regulations introduction
    13.2.1 Implementation Plan for the Recent Priorities of the Health Care System Reform
    13.2.2 Drug Administration Law of The People's Republic of China
    13.2.3 Provisions on Supervision and Administration of Pharmaceutical Manufacturing
    13.2.4 Provisions for Drug Registration Administration
    13.2.5 Measures for the Examination of Drug Advertisements
    13.2.6 Provisions on Approval of Generic Drugs
    13.2.7 Drug GMP Certification

图表目录
本报告目录与内容系中投顾问原创,未经中投顾问书面许可及授权,拒绝任何形式的复制、转载,谢谢!

如果报告内容未能满足您的需求,请了解我们的报告定制服务>>

Investment and Forecast Report on China Chemical Medicine Industry, 2024-2028

    中投影响力

    资质荣誉 媒体合作 公司动态

    外商投资企业协会会员单位外商投资企业协会会员单位

    最具品牌价值行业门户最具品牌价值行业门户

    发改委十佳创新案例金典奖发改委十佳创新案例金典奖

    电子行业协会副会长单位电子行业协会副会长单位

    哈尔滨最佳项目策划智库单位哈尔滨最佳项目策划智库单位

    深圳市商业联合会会员单位深圳市商业联合会会员单位

    珠海招商合伙人珠海招商合伙人

    重庆市产业招商联盟单位重庆市产业招商联盟单位

    中投顾问协办的济阳区(深圳) "新能源汽车产业"专题推介会中投顾问协办的济阳区(深圳) "新能源汽车产业"专题推介会

    中投顾问受邀为合肥市投促部门作机器人产业招商培训中投顾问受邀为合肥市投促部门作机器人产业招商培训

    中投顾问为珠海全市招商系统培训产业招商大脑获得圆满成功中投顾问为珠海全市招商系统培训产业招商大脑获得圆满成功

    中投顾问为汉中市作"大数据招商、精准招商"培训中投顾问为汉中市作"大数据招商、精准招商"培训

    中投顾问项目组赴安庆迎江经开区调研中投顾问项目组赴安庆迎江经开区调研

    湖州市吴兴区驻深办来访中投顾问湖州市吴兴区驻深办来访中投顾问

    河北邢台南宫市驻深领导赴中投顾问拜访河北邢台南宫市驻深领导赴中投顾问拜访

    中投顾问陪同广州某经开区领导赴外商协会治谈合作中投顾问陪同广州某经开区领导赴外商协会治谈合作

    微信扫一扫关注公众号"中投顾问"(ID :touziocn),回复""即可获取。

    知道了
    QQ咨询
    在线客服